Immune profiling of in NSCLC shows expression of PD-L1 in macrophages is better associated with outcomes than PD-L1 in tumor cells in PD-1 axis immunotherapy treated patients

被引：0
|
作者：
Liu, Yuting [1 ]
Zugazagoitia, Jon [1 ]
Henick, Brian [1 ]
Schalper, Kurt A. [1 ]
Rimm, David L. [1 ]
机构：
[1] Yale Univ, New Haven, CT USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-2674
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2674
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
    Janning, Melanie
    Kobus, Franca
    Babayan, Anna
    Wikman, Harriet
    Velthaus, Janna-Lisa
    Bergmann, Sonja
    Schatz, Stefanie
    Falk, Markus
    Berger, Lars-Arne
    Boettcher, Lisa-Marie
    Paesler, Sarina
    Gorges, Tobias M.
    O'Flaherty, Linda
    Hille, Claudia
    Joosse, Simon A.
    Simon, Ronald
    Tiemann, Markus
    Bokemeyer, Carsten
    Reck, Martin
    Riethdorf, Sabine
    Pantel, Klaus
    Loges, Sonja
    CANCERS, 2019, 11 (06):
  • [2] PD-1/PD-L1 axis importance and tumor microenvironment immune cells
    Lotfinejad, Parisa
    Kazemi, Tohid
    Mokhtarzadeh, Ahad
    Shanehbandi, Dariush
    Niaragh, Farhad Jadidi
    Safaei, Sahar
    Asadi, Milad
    Baradaran, Behzad
    LIFE SCIENCES, 2020, 259
  • [3] Relevance of host and tumor PD-L1 expression in PD-L1 and PD-1 blockade
    Lin, Heng
    Wei, Shuang
    Vatan, Linda
    Kryczek, Ilona
    Zou, Weiping
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [4] Macrophages are important source of PD-L1 and PD-L1 expressing in macrophages affect the prognosis of NSCLC patients with tumor PD-L1 negative
    Liu, Y.
    Cao, L.
    Che, X.
    Qiu, X.
    Li, Z.
    Yang, B.
    Wang, S.
    Qu, X.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 531 - 532
  • [5] Monitoring PD-L1 expression on circulating stromal cells in blood predicts PFS and OS in patients with metastatic NSCLC treated with PD-L1/PD-1 immunotherapy.
    Moran, Jillian
    Adams, Daniel L.
    Bravo, Pablo Lopez
    He, Jianzhong
    Qiao, Yawei
    Xu, Ting
    Liao, Zhongxing X.
    Gardner, Kirby P.
    Tang, Cha-Mei
    Lin, Steven H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment
    Gumuzio, Juan
    Calleja, Veronique
    Miles, James
    Sancehz-Magraner, Lissete
    Aguirre, Fernando
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [7] Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
    Fei Tang
    Pan Zheng
    Cell & Bioscience, 8
  • [8] Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
    Tang, Fei
    Zheng, Pan
    CELL AND BIOSCIENCE, 2018, 8
  • [9] PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
    Liu, Jinhua
    Chen, Zichao
    Li, Yaqun
    Zhao, Wenjie
    Wu, JiBiao
    Zhang, Zhen
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [10] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
12345